Methods and systems for assessing biological materials using optical and spectroscopic detection techniques

• US 6,573,063 B2
• Filed: 10/30/2001
• Issued: 06/03/2003
• Est. Priority Date: 10/04/1995
• Status: Expired due to Fees

• Current Assignee: Neurotherapeutics Pharma LLC
• Original Assignee: Cytoscan Sciences, LLC
• Inventors: Hochman, Daryl W.
• Primary Examiner(s): Leary, Louise N.
• Application Number:
  US10/001,366
• Publication Number:
  US 20020055092A1
• Time in Patent Office: 581 Days
• Field of Search: 435/29, 435/4, 435/30, 435/288.7, 435/32, 435/968
• US Class Current: 435/29
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C12Q 1/02 involving viable microorganisms
• CPC Class Codes: G01N 33/5005 involving human or animal cells immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

Optical detection techniques for the assessment of the physiological state, health and/or viability of biological materials are provided. Biological materials which may be examined using such techniques include cells, tissues, organs and subcellular components. The inventive techniques may be employed in high throughput screening of potential diagnostic and/or therapeutic agents.

Claims

1. A method for assessing the physiological condition of a sample biological population:

maintaining at least one sample population of biological material in a viable condition;

administering a contrast agent to the sample population;

acquiring a test data set containing information relating to one or more optical properties of resolved spatial locations within the sample population following administration of the contrast agent;

comparing the test data set to a comparison data set, wherein the comparison data set contains information relating to one or more optical properties of a predetermined sample population having a predetermined physiological condition; and

assessing the response of the sample population to the administration of the contrast agent based on the comparison.

2. A method of claim 1, additionally comprising acquiring a plurality of test data sets at a plurality of time points following administration of the contrast agent and wherein the comparison data set(s) contain(s) data relating to one or more optical properties of the sample biological population at different time points following administration of the contrast agent.

3. A method of claim 1, wherein the optical property is selected from the group consisting of:

optical scattering;

optical absorption;

birefringence;

fluorescence and phosphorescence.

4. A method of claim 1, wherein the physiological condition is selected from the group consisting of:

viable;

non-viable;

necrotic;

apoptotic;

proliferating;

malignant;

intracellular and extracellular pH;

intracellular and extracellular reactive oxygen species;

intracellular and extracellular calcium, chloride, zinc, magnesium, sodium, and potassium levels, intracellular ATP levels, cell membrane potentials;

electrical-and neuronal activity; and

hemodynamic properties.

5. A method of claim 1, wherein the sample population is in a viable, healthy condition prior to administration of the contrast agent.

6. A method of claim 1, additionally comprising administering a physiological challenge prior to administering the contrast agent.

7. A method of claim 6, wherein the challenge comprises an agent selected from the group consisting of:

pathogens, pollutants;

radiation;

chemotherapeutic agents;

immumodulatory agents;

biological agents;

infectious agents;

apoptotic agents;

necrotic agents;

mechanical insult;

stress;

aging agents;

or disease agents.

8. A method of claim 1, additionally comprising admnistering a test agent prior to administering the contrast agent.

9. A method of claim 1, additionally comprising administering a physiological challenge or a test agent following the acquisition of the test data and acquiring a second test data set following administration of the physiological challenge or test agent.

10. A method of claim 9, additionally comprising administering a contrast agent following administration of the physiological challenge or test agent.

11. A method of claim 1, wherein the sample population of biological material is genetically modified.

12. A method of claim 1, wherein the sample population of biological material comprises pathological cells.

13. A method of claim 1, additionally comprising simulating a disease state in the sample population prior to administration of the contrast agent.

14. A method for screening a candidate compound for activity as a diagnostic or therapeutic agent, comprising:

maintaining at least one sample population of biological material;

introducing a candidate compound and a contrast agent to the sample population;

acquiring and recording at least one test data set corresponding to one or more optical properties of the sample population following introduction of the candidate compound;

comparing the test data set to a comparison data set, wherein the comparison data set corresponds to one or more optical properties of a predetermined sample population having a predetermined physiological state; and

assessing the activity of the candidate compound as a diagnostic or therapeutic agent based on the comparison between the test data set and the comparison data set.

15. The method of claim 14, wherein the optical property is selected from the group consisting of:

optical scattering;

optical absorption;

birefringence;

fluorescence and phosphorescence.

16. The method of claim 14, wherein the sample population of biological material comprises pathological cells.

17. The method of claim 14, wherein the sample population of biological material comprises malignant cells.

18. The method of claim 14, wherein the sample population of biological material comprises dysfunctional cells.

19. The method of claim 14, wherein the candidate compound is suspected of having activity as a chloride cotransporter agonist or antagonist.